Minerva Neurosciences, Inc.
NASDAQ:NERVBiotechnology
-$0.30 today
- Market cap
- $107.64M
- Beta
- -0.11
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$8.46
Volume 0.15M
Average 0.21M
Returns on capital
Minerva Neurosciences, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
208.5%
avg -51.9%
ROIC
-15.8%
avg -40.1%
ROA
-299.5%
avg -61.0%
Analysis
ROE is currently the strongest return metric at 208.5% versus its period average of -51.9%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Remy Luthringer | Executive Chairman, CEO & Member of Scientific Advisory Board | USD 1.16M | 65 | 1.69M | 3.63% |
Michael Davidson | Member of Scientific Advisory Board & Chief Medical Officer | USD 657.47K | 76 | 85.00K | 0.18% |
Frederick W. Ahlholm | Senior Vice President, Chief Financial Officer & Secretary | USD 649.21K | 60 | 680.00K | 1.46% |
Joseph Reilly | Senior Vice President & Chief Operating Officer | USD 461K | 51 | — | — |
Anthony Aliquo | Chief Accounting Officer & Principal Accounting Officer | — | 39 | 1.68K | <0.01% |
James O'Connor | Chief Business Officer & General Counsel | — | 52 | — | — |
William Boni | Vice President of Investor Relations & Corporation Communications | — | 74 | — | — |
Compensation is shown in the reported currency; data updated Nov 18, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Aug 10, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Competitors
Who does Minerva Neurosciences, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about NERV's management, answered from reported figures.
Who manages NERV?
Minerva Neurosciences, Inc. (NERV) lists 7 active executives. The top listed executive is Remy Luthringer, Executive Chairman, CEO & Member of Scientific Advisory Board.
Are NERV insiders buying or selling?
Recent insider activity shows net buying of $64.00M.
Continue the stock analysis
Jump to another research area for this company.